Novavax will use the occasion of the 2024 World Vaccine Congress, to be held in Washington DC from April 2 to 4, 2024, to present data on its updated COVID-19 vaccine (NVX-CoV2601), as well as on its candidate vaccines against influenza and the COVID-19-Influenza combination (CIC).
The company has already announced that recent data on its updated XBB.1.5 COVID-19 vaccine have shown strong neutralizing antibody titers for the XBB.1.5 sub-variant, as well as for the JN.1 sub-variant currently in circulation.
Novavax will also discuss its influenza and CIC vaccine candidates, including a recap of data to date and the timeline for the Phase 3 trial due to start in the second half of 2024.
Dr. Robert Walker, Novavax's Chief Medical Officer, will participate in a panel discussion on the future of COVID-19 vaccinations on April 3, exploring the benefits of developing broadly protective antigens or combination vaccines.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Companyâs proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
NOVAVAX, INC. 
